Moomoo AIのまとめ
Senti Biosciences, Inc., a Delaware-incorporated biotechnology company, has announced significant changes to its executive team in a recent Form 8-K filing with the SEC. Timothy Lu, M.D., Ph.D., currently serving as the CEO and President, has been appointed as the interim principal financial officer and principal accounting officer, effective May 4, 2024. This appointment follows the Board's approval on April 26, 2024, and will last until a permanent successor is appointed or until Lu's earlier departure from the role. Additionally, Yvonne Li has been appointed as the Interim Chief Financial Officer, also effective May 4, 2024. Li's appointment will become official immediately after the filing of the company's Quarterly Report for the fiscal quarter ended March 31, 2024. In conjunction with her appointment, Li has entered into a consulting agreement with Senti Biosciences, which includes a consulting fee of $350 per hour and a maximum aggregate payment of $370,000. The company plans to provide a full description of the Li Consulting Agreement in its upcoming Quarterly Report for the fiscal quarter ending June 30, 2024.
Senti Biosciences, Inc., a Delaware-incorporated biotechnology company, has announced significant changes to its executive team in a recent Form 8-K filing with the SEC. Timothy Lu, M.D., Ph.D., currently serving as the CEO and President, has been appointed as the interim principal financial officer and principal accounting officer, effective May 4, 2024. This appointment follows the Board's approval on April 26, 2024, and will last until a permanent successor is appointed or until Lu's earlier departure from the role. Additionally, Yvonne Li has been appointed as the Interim Chief Financial Officer, also effective May 4, 2024. Li's appointment will become official immediately after the filing of the company's Quarterly Report for the fiscal quarter ended March 31, 2024. In conjunction with her appointment, Li has entered into a consulting agreement with Senti Biosciences, which includes a consulting fee of $350 per hour and a maximum aggregate payment of $370,000. The company plans to provide a full description of the Li Consulting Agreement in its upcoming Quarterly Report for the fiscal quarter ending June 30, 2024.
米国デラウェア州に本拠を置くバイオテクノロジー企業のSenti Biosciences, Inc.は、最近、SECに提出されたForm 8-Kにおいて、経営陣に重要な人事異動があったことを発表しました。CEO兼社長を務めるTimothy Lu、M.D.、Ph.D.は、2024年5月4日から有効となり、常勤後継者が任命されるか、またはLuが役割から早期に退任するまで、暫定の財務責任者および主要会計責任者に任命されました。この任命は、2024年4月26日の取締役会の承認に続くものです。さらに、Yvonne Li氏が2024年5月4日から暫定の最高財務責任者に任命されました。Li氏の任命は、2024...すべて展開
米国デラウェア州に本拠を置くバイオテクノロジー企業のSenti Biosciences, Inc.は、最近、SECに提出されたForm 8-Kにおいて、経営陣に重要な人事異動があったことを発表しました。CEO兼社長を務めるTimothy Lu、M.D.、Ph.D.は、2024年5月4日から有効となり、常勤後継者が任命されるか、またはLuが役割から早期に退任するまで、暫定の財務責任者および主要会計責任者に任命されました。この任命は、2024年4月26日の取締役会の承認に続くものです。さらに、Yvonne Li氏が2024年5月4日から暫定の最高財務責任者に任命されました。Li氏の任命は、2024年3月31日の財務四半期報告書の提出直後に公式化されます。任命に伴い、Li氏はSenti Biosciencesとのコンサルティング契約に署名し、コンサルティング料は時間あたり350ドル、最大支払額は37万ドルとなります。会社は、2024年6月30日締めの財務四半期報告書でLi氏とのコンサルティング契約の完全な説明を提供する予定です。
役に立った
役に立たない
この開示の添付ファイルは以下です：